ARS Total Assets from 2010 to 2026

SPRY Stock

8.88 0.07 0.79%

ARS Pharmaceuticals Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2026. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-12-31

Previous Quarter

313.5 M

Current Value

372.8 M

Quarterly Volatility

118.8 M

Covid

Interest Hikes

Check ARS Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 K, Gross Profit of 82.8 M or Other Operating Expenses of 111.4 M, as well as many indicators such as Price To Sales Ratio of 9.81, Dividend Yield of 0.0 or PTB Ratio of 3.76. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with ARS Stock

Check out the analysis of ARS Pharmaceuticals Correlation against competitors.

For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals guide.

The evolution of Total Assets for ARS Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how ARS Pharmaceuticals compares to historical norms and industry peers.

Latest ARS Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of ARS Pharmaceuticals over the last few years. Total assets refers to the total amount of ARS Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ARS Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. ARS Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARS Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 351.15 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

ARS Total Assets Regression Statistics

	Arithmetic Mean	120,296,600
	Geometric Mean	57,868,133
	Coefficient Of Variation	125.61
	Mean Deviation	128,486,612
	Median	27,547,000
	Standard Deviation	151,098,568
	Sample Variance	22830.8T
	Range	408.4M
	R-Value	0.81
	Mean Square Error	8407.2T
	R-Squared	0.65
	Significance	0.000084
	Slope	24,212,315
	Total Sum of Squares	365292.4T

ARS Total Assets History

	2026	424 M
	2025	403.8 M
	2024	351.2 M
	2023	233.2 M
	2022	281.4 M
	2021	61.4 M
	2020	26.4 M

Other Fundumenentals of ARS Pharmaceuticals

Intangibles To Total Assets

ARS Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Capital Surpluse	Intangible Assets
Total Assets		0.97	-0.56	-0.9	0.86	0.71	1.0	-0.66	0.98	-0.89	-0.88	0.89	0.92	0.87	-0.95	0.94	-0.86	0.66	-0.7	0.81
Total Stockholder Equity	0.97		-0.64	-0.91	0.75	0.53	0.98	-0.68	0.99	-0.88	-0.83	0.8	0.96	0.82	-0.99	0.94	-0.81	0.55	-0.62	0.72
Net Debt	-0.56	-0.64		0.43	-0.14	-0.11	-0.58	0.51	-0.63	0.72	0.66	-0.16	-0.69	-0.62	0.65	-0.65	0.68	-0.54	0.09	-0.12
Retained Earnings	-0.9	-0.91	0.43		-0.74	-0.54	-0.9	0.49	-0.93	0.87	0.83	-0.75	-0.89	-0.8	0.93	-0.89	0.82	-0.59	0.53	-0.7
Accounts Payable	0.86	0.75	-0.14	-0.74		0.88	0.85	-0.37	0.75	-0.6	-0.67	0.98	0.66	0.67	-0.7	0.73	-0.64	0.51	-0.79	0.92
Total Liab	0.71	0.53	-0.11	-0.54	0.88		0.7	-0.37	0.56	-0.58	-0.71	0.84	0.47	0.71	-0.49	0.59	-0.69	0.73	-0.69	0.8
Total Current Assets	1.0	0.98	-0.58	-0.9	0.85	0.7		-0.67	0.98	-0.9	-0.89	0.87	0.93	0.88	-0.96	0.95	-0.87	0.67	-0.69	0.8
Short Term Debt	-0.66	-0.68	0.51	0.49	-0.37	-0.37	-0.67		-0.66	0.64	0.61	-0.51	-0.65	-0.6	0.66	-0.65	0.6	-0.45	0.37	-0.47
Net Tangible Assets	0.98	0.99	-0.63	-0.93	0.75	0.56	0.98	-0.66		-0.91	-0.86	0.79	0.96	0.85	-0.99	0.95	-0.85	0.6	-0.61	0.71
Current Deferred Revenue	-0.89	-0.88	0.72	0.87	-0.6	-0.58	-0.9	0.64	-0.91		0.98	-0.62	-0.91	-0.96	0.9	-0.92	0.98	-0.84	0.42	-0.59
Long Term Debt	-0.88	-0.83	0.66	0.83	-0.67	-0.71	-0.89	0.61	-0.86	0.98		-0.67	-0.85	-0.98	0.84	-0.89	1.0	-0.91	0.48	-0.64
Net Receivables	0.89	0.8	-0.16	-0.75	0.98	0.84	0.87	-0.51	0.79	-0.62	-0.67		0.7	0.67	-0.75	0.76	-0.64	0.48	-0.8	0.94
Net Invested Capital	0.92	0.96	-0.69	-0.89	0.66	0.47	0.93	-0.65	0.96	-0.91	-0.85	0.7		0.86	-0.98	0.99	-0.83	0.57	-0.41	0.71
Short Long Term Debt	0.87	0.82	-0.62	-0.8	0.67	0.71	0.88	-0.6	0.85	-0.96	-0.98	0.67	0.86		-0.82	0.91	-0.96	0.88	-0.46	0.7
Capital Stock	-0.95	-0.99	0.65	0.93	-0.7	-0.49	-0.96	0.66	-0.99	0.9	0.84	-0.75	-0.98	-0.82		-0.95	0.82	-0.56	0.53	-0.68
Net Working Capital	0.94	0.94	-0.65	-0.89	0.73	0.59	0.95	-0.65	0.95	-0.92	-0.89	0.76	0.99	0.91	-0.95		-0.87	0.65	-0.44	0.79
Common Stock	-0.86	-0.81	0.68	0.82	-0.64	-0.69	-0.87	0.6	-0.85	0.98	1.0	-0.64	-0.83	-0.96	0.82	-0.87		-0.93	0.46	-0.59
Property Plant Equipment	0.66	0.55	-0.54	-0.59	0.51	0.73	0.67	-0.45	0.6	-0.84	-0.91	0.48	0.57	0.88	-0.56	0.65	-0.93		-0.39	0.45
Capital Surpluse	-0.7	-0.62	0.09	0.53	-0.79	-0.69	-0.69	0.37	-0.61	0.42	0.48	-0.8	-0.41	-0.46	0.53	-0.44	0.46	-0.39		-0.57
Intangible Assets	0.81	0.72	-0.12	-0.7	0.92	0.8	0.8	-0.47	0.71	-0.59	-0.64	0.94	0.71	0.7	-0.68	0.79	-0.59	0.45	-0.57

Click cells to compare fundamentals

About ARS Pharmaceuticals Financial Statements

ARS Pharmaceuticals investors use historical fundamental indicators, such as ARS Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ARS Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	403.8 M	424 M
Intangibles To Total Assets	0.02	0.02

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC